2. Search Result
Search Result
Results for "

C57 mice

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0921
    Succinylsulfathiazole
    1 Publications Verification

    Succinylsulphathiazole

    		 Antibiotic Bacterial Dihydrofolate reductase (DHFR) mTOR Infection
    Succinylsulfathiazole (Succinylsulphathiazole) is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice .
    Succinylsulfathiazole
  • HY-N0538
    Xylitol

    Xylite

    		 Environmental Pollutants Endogenous Metabolite Bacterial Autophagy Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol
  • HY-W052508
    Norquetiapine
    1 Publications Verification

    N-Desalkylquetiapine

    		 Drug Metabolite 5-HT Receptor HCN Channel Serotonin Transporter Neurological Disease
    Norquetiapine ( N-Desalkylauetiapine), a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC50 of 13.9 μM. Norquetiapine selectively inhibits noradrenaline reuptake, is a partial 5-HT1A (Ki = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (Ki = 237 nM), 5-HT2C(Ki = 107 nM), and 5-HT7 (Ki = 76 nM) receptors. Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine can be used for the study of depression and inflammation .
    Norquetiapine
  • HY-117427
    D5D-IN-326
    2 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-149874
    BMS-502
    1 Publications Verification

    		 DGK Inflammation/Immunology Cancer
    BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .
    BMS-502
  • HY-N10549
    Gigantol
    1 Publications Verification

    		 Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3 Infection Metabolic Disease Cancer
    Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury .
    Gigantol
  • HY-172930
    PVTX-405

    		Molecular Glues IKZF Family Potassium Channel Inflammation/Immunology Cancer
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
    PVTX-405
  • HY-101122
    LX2761

    		SGLT GLP Receptor Metabolic Disease
    LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .
    LX2761
  • HY-W052508S
    Norquetiapine-d8

    N-Desalkylquetiapine-d8

    		 Isotope-Labeled Compounds Others Neurological Disease Inflammation/Immunology
    Norquetiapine-d8 (N-Desalkylquetiapine-d8) is the deuterium labeled Norquetiapine.Norquetiapine ( N-Desalkylauetiapine), a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC50 of 13.9 μM. Norquetiapine selectively inhibits noradrenaline reuptake, is a partial 5-HT1A (Ki = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (Ki = 237 nM), 5-HT2C(Ki = 107 nM), and 5-HT7 (Ki = 76 nM) receptors. Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine can be used for the study of depression and inflammation .
    Norquetiapine-d8
  • HY-177406
    VR11 aptamer

    		TNF Receptor Apoptosis NO Synthase Inflammation/Immunology
    VR11 aptamer is a DNA-based TNF-α inhibitor with a KD of 7.0 nM. VR11 aptamer prevents TNFα-induced apoptosis and NO production. VR11 aptamer has non-immunogenicity and does not raise immune responses when injected intraperitoneally into C57BL/6 mice model. VR11 aptamer can be used for inflammatory diseases research .
    VR11 aptamer
  • HY-175660
    KCL-HO-1i

    		Heme Oxygenase (HO) Cancer
    KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor (rat HO-1: IC50 = 123 nM) and human HO-1: IC50 = 128 nM). KCL-HO-1i targets immunosuppressive LYVE-1 + perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME), reduces PvTAM-mediated immune exclusion. KCL-HO-1i demonstrates synergistic anti-tumor efficacy with chemotherapy in MMTV-PyMT spontaneous breast cancer mice or C57Bl/6 mice bearing subcutaneous MN-MCA1 sarcomas. KCL-HO-1i can be used for the study of cancer .
    KCL-HO-1i
  • HY-W040555
    Norquetiapine dihydrochloride
    1 Publications Verification

    N-Desalkylquetiapine dihydrochloride

    		 Drug Metabolite 5-HT Receptor HCN Channel Serotonin Transporter Neurological Disease
    Norquetiapine ( N-Desalkylauetiapine) dihydrochloride, a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC50 of 13.9 μM. Norquetiapine dihydrochloride selectively inhibits noradrenaline reuptake, is a partial 5-HT1A (Ki = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (Ki = 237 nM), 5-HT2C(Ki = 107 nM), and 5-HT7 (Ki = 76 nM) receptors. Norquetiapine dihydrochloride blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine dihydrochloride shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine dihydrochloride can be used for the study of depression and inflammation .
    Norquetiapine dihydrochloride
  • HY-163363
    β-AR antagonist 2

    		Adrenergic Receptor Cancer
    β-AR antagonist 2 (compound 43) is an antagonist of β-AR (IC50: 0.17 μM). β-AR-IN-1 inhibits the growth of mouse A549 xenograft tumors and shows cardioprotective efficacy against DOX-induced HF in C57 mice .
    β-AR antagonist 2
  • HY-162710
    LTA4H-IN-5

    		Aminopeptidase Inflammation/Immunology
    LTA4H-IN-5 (Compound H122) is an orally active inhibitor for leukotriene A4 hydrolase (LTA4H), that inhibits the LTA4H aminopeptidase and LTA4H hydrolase with IC50 of 0.38 nM and 16.93 nM. LTA4H-IN-5 exhibits good pharmacokinetic characteristics in C57 mice and ameliorates the DNBS-induced ulcerative enteritis in rat models .
    LTA4H-IN-5
  • HY-128435
    2,4'-Dihydroxybenzophenone-1

    		Estrogen Receptor/ERR Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-157429
    25N-N1-Nap

    		5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-117236
    GSI-136

    		γ-secretase Neurological Disease
    GSI-136 is an inhibitor of γ-secretase with an IC50 of 3 nM. GSI-136 can lead to a dose-dependent reduction of Aβ40 levels in diethylamine-extracted brain homogenates of C57BL/6 mice. GSI-136 can be studied in medicinal chemistry and Alzheimer's disease research .
    GSI-136
  • HY-D1056A5
    Lipopolysaccharides, from E. coli K-235

    LPS, from Escherichia coli (K-235)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) K-235 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli K-235 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from E. coli K-235 have a mitogenic effect on C57BL/10ScN spleen cells. Additionally, LPS purified using butanol and deoxycholic acid methods stimulates spleen cells in C57BL/10ScCR and C3H/HeJ mice .
    It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
    Lipopolysaccharides, from E. coli K-235
  • HY-101384
    Ro 10-5824

    		Dopamine Receptor Neurological Disease
    Ro 10-5824 is a potent and selective D4R partial agonist with a Ki of 5.2 nM. Ro 10-5824 increases novel object exploration in C57 mice .
    Ro 10-5824
  • HY-160025
    IDO antagonist-1

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-153350
    ERK-IN-7

    		ERK Cancer
    ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC50 of 5 nM and 7 nM against ERK1 and ERK2, respectively .
    ERK-IN-7
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-174260
    Neuroprotective agent 11

    		NO Synthase COX Caspase MDM-2/p53 Neurological Disease
    Neuroprotective agent 11 (Compound 1a) is an orally active polyphenol compound with significant protective effects against cerebral ischemia. The main activities of Neuroprotective agent 11 include inhibiting neuronal inflammation and apoptosis, reducing cerebral infarction volume, and improving behavioral symptoms of cerebral ischemic mice. Neuroprotective agent 11 exerts its regulatory mechanism by downregulating the expression of inflammatory factors (iNOS、COX-2) and apoptotic proteins (cleaved-Caspase3, p53). Neuroprotective agent 11 can be used in the study of cerebral ischemia-related diseases (such as ischemic stroke) .
    Neuroprotective agent 11
  • HY-B0921R
    Succinylsulfathiazole (Standard)

    Succinylsulphathiazole (Standard)

    		 Reference Standards Bacterial Antibiotic Dihydrofolate reductase (DHFR) mTOR Infection
    Succinylsulfathiazole (Standard) (Succinylsulphathiazole) is the analytical standard of Succinylsulfathiazole (HY-B0921). This product is intended for research and analytical applications. Succinylsulfathiazole is a long-acting sulfonamide antibiotic with localized gut-specific antibacterial activity and is orally active. Succinylsulfathiazole inhibits bacterial folate synthesis, reduces coliform counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes gut folate-producing bacteria. Succinylsulfathiazole modulates hepatic mTOR signaling, diminishes cecal fermentation, decreases hepatic folate levels and total folate excretion, elevates nitrogen excretion and reduces the fermentability of certain dietary fibers. Succinylsulfathiazole induces folate deficiency and triggers biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice .
    Succinylsulfathiazole (Standard)
  • HY-144786
    Tubulin polymerization-IN-4

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-4 is a potent tubulin polymerization inhibitor with IC50 value of 4.6 μM. Tubulin polymerization-IN-4 can disrupt tubulin polymerization and vasculature, arrest the cell cycle at the G2/M phase, induce apoptosis, and suppress clonogenesis and migration in HeLa cells. Tubulin polymerization-IN-4 can be used for researching cervical cancer .
    Tubulin polymerization-IN-4
  • HY-W768347
    Xylitol-13C5

    Xylite-13C5

    		 Isotope-Labeled Compounds Bacterial Autophagy Endogenous Metabolite Atg8/LC3 Atg7 Cancer
    Xylitol- 13C5 (Xylite- 13C5) is the 13C-labeled Xylitol (HY-N0538). Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol-13C5
  • HY-171837A
    t9,t11,c15-CLNA

    		TNF Receptor Interleukin Related SOD Inflammation/Immunology
    t9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. t9,t11,c15-CLNA has the main activities of anti-inflammatory, antioxidant and improving intestinal barrier function. The regulatory mechanism of t9,t11,c15-CLNA includes upregulation of tight junction proteins, inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6) and activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be used in the study of inflammatory bowel diseases (such as colitis) .
    t9,t11,c15-CLNA
  • HY-173309
    P53/TLR2 modulator-1

    		MDM-2/p53 Toll-like Receptor (TLR) Apoptosis MyD88 Bcl-2 Family Interleukin Related Cancer
    P53/TLR2 modulator-1 (Compound Z9) is a modulator that targets both the P53 pathway and TLR2 simultaneously, exhibiting anti-radiation activity. P53/TLR2 modulator-1 reduces apoptosis by inhibiting the radiation-induced expression of P53 and Bax. At the same time, it activates the TLR2 pathway, upregulates the expression of downstream proteins MyD88 and P65, and promotes the secretion of cytokines such as IL-6, thus exerting an anti-radiation effect. P53/TLR2 modulator-1 shows significant anti-radiation activity against both AHH-1 cells and HUVECs. It can also increase the survival rate of C57BL/6J mice irradiated with a lethal dose of radiation and reduce the damage to their hematopoietic system, the villous structure of the small intestine, and the spleen caused by radiation. P53/TLR2 modulator-1 can be used in the research of radiation injury-related diseases .
    P53/TLR2 modulator-1
  • HY-P11699
    AAPDNRETF

    		Inflammation/Immunology
    AAPDNRETF is a dominant minor histocompatibility antigen presented by H-2D b， which antigen is expressed in C57BL/6 mice and can be recognized by T cells from C3H.SW mice, thereby inducing a strong immune response. AAPDNRETF can induce graft-versus-host disease in irradiated C57BL/6 recipient mice via transfer of sensitized T lymphocytes. AAPDNRETF is applicable to the research of graft-versus-host disease .
    AAPDNRETF
  • HY-148640
    WK500B

    		BCL6 MDM-2/p53 Histone Methyltransferase CXCR Apoptosis Cancer
    WK500B is a potent and orally active BCL6 inhibitor with a KD of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL) .
    WK500B
  • HY-182712
    HPSE-IN-2

    		Glycosidase Cancer
    HPSE-IN-2 is a heparanase (HPSE) inhibitor with an IC50 of 0.27 µM. HPSE-IN-2 reduces lung metastasis in mouse models. HPSE-IN-2 can be used for the research of melanoma .
    HPSE-IN-2
  • HY-D3226
    Zinc(II) probe-1

    		Fluorescent Dye Neurological Disease
    Zinc (II) probe-1 (Compound DNP) is a dual-color Fluorescent probe that can simultaneously monitor Zn 2+ and H +. Upon interaction with Zn 2+, Zinc (II) probe-1 produces bright blue fluorescence (excitation wavelength: 405 nm; blue channel wavelength: 420-500 nm). Upon interaction with H +, Zinc (II) probe-1 exhibits red fluorescence (excitation wavelength: 561 nm; red channel emission wavelength: 630-730 nm). Zinc (II) probe-1 can be used in studies related to depression .
    Zinc(II) probe-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: